Portal de Periódicos da CAPES

Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: Development of extracutaneous lymphoma in 6 patients∗

2005; Elsevier BV; Volume: 52; Issue: 6 Linguagem: Inglês

10.1016/j.jaad.2005.02.055

1097-6787

Saskia A. Bouwhuis, Mark D.P. Davis, Rokea A. el‐Azhary, Marian T. McEvoy, Lawrence E. Gibson, John M. Knudsen, Joseph M. Kist, Mark R. Pittelkow,

Fungal Infections and Studies

Bexarotene is a retinoid drug that is approved for the treatment of cutaneous T-cell lymphoma. We report 6 cases in which the initiation of bexarotene therapy for cutaneous T-cell lymphoma was temporally associated with the progression of internal disease despite improvement in cutaneous signs and symptoms. It is possible that bexarotene contributed to this progression. Although bexarotene therapy may alleviate symptoms and signs of cutaneous T-cell lymphoma, careful surveillance of lymph nodes and solid organs during treatment is advised.